ResearcherThe University of Texas MD Anderson Cancer CenterNo recent work listed
Kanwal P. S. Raghav
Matched on ORCID iD 0000-0003-1311-4173; OpenAlex author ID A5015321333, A5032970786.
Their work
Counts cover pancreatic cancer work only: a researcher’s other papers, trials and grants are not in these records.
- Pancreatic cancer papers
- 3
- Pancreatic cancer trials
- 1 (principal investigator on 1)
- Pancreatic cancer grants
- 0
- Collaborators
- 15
2017: 1 trial · 2018: none · 2019: none · 2020: 2 papers · 2021: 1 paper
Papers 3
- Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. Co-author DOI 10.21037/jgo-20-569↗
- Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.3229↗
- Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Co-author DOI 10.1016/j.pan.2020.01.005↗
Trials 1
- Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors Principal investigator NCT03074513↗
Closest collaborators
The 15 strongest of 15 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Michael James Overman · 3 shared papers, 2020–2021
- Paper Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. DOI 10.21037/jgo-20-569↗
- Paper Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. DOI 10.1016/j.pan.2020.01.005↗
- Paper Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. DOI 10.1002/cam4.3229↗
- Rachna T. Shroff · 3 shared papers, 2020–2021
- Paper Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. DOI 10.21037/jgo-20-569↗
- Paper Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. DOI 10.1016/j.pan.2020.01.005↗
- Paper Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. DOI 10.1002/cam4.3229↗
- Milind M. Javle · 3 shared papers, 2020–2021
- Paper Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. DOI 10.21037/jgo-20-569↗
- Paper Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. DOI 10.1016/j.pan.2020.01.005↗
- Paper Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. DOI 10.1002/cam4.3229↗
- Jonathan D. Mizrahi · 3 shared papers, 2020–2021
- Paper Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. DOI 10.21037/jgo-20-569↗
- Paper Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. DOI 10.1016/j.pan.2020.01.005↗
- Paper Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. DOI 10.1002/cam4.3229↗
- Robert A. Wolff · 3 shared papers, 2020–2021
- Paper Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. DOI 10.21037/jgo-20-569↗
- Paper Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. DOI 10.1016/j.pan.2020.01.005↗
- Paper Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. DOI 10.1002/cam4.3229↗
- Jane Elizabeth Rogers · 3 shared papers, 2020–2021
- Paper Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. DOI 10.21037/jgo-20-569↗
- Paper Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. DOI 10.1016/j.pan.2020.01.005↗
- Paper Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. DOI 10.1002/cam4.3229↗
- Gauri Rajani Varadhachary · 3 shared papers, 2020–2021
- Paper Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. DOI 10.21037/jgo-20-569↗
- Paper Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. DOI 10.1016/j.pan.2020.01.005↗
- Paper Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. DOI 10.1002/cam4.3229↗
- Shubham Pant · 3 shared papers, 2020–2021
- Paper Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. DOI 10.21037/jgo-20-569↗
- Paper Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. DOI 10.1016/j.pan.2020.01.005↗
- Paper Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. DOI 10.1002/cam4.3229↗
- David R. Fogelman · 2 shared papers, 2020
- Graciela M. Nogueras-González · 1 shared paper, 2021
- Rishi Surana · 1 shared paper, 2021
- Kenneth R. Hess · 1 shared paper, 2020
- Linus Ho · 1 shared paper, 2020
- Chirayu Mohindroo · 1 shared paper, 2020
- Florencia M. McAllister · 1 shared paper, 2020
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.